BioSpace News Archive

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City.

Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, today announced the closing of its initial public offering of 12,535,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of the ClearPoint Neuro Navigation software.

The Rockefeller Foundation announces it will commit US$15 million to the Global Fund to Fight AIDS, tuberculosis, and malaria ahead of the Fund’s Seventh Replenishment Conference on Wednesday, September 21.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases.

Viracta Therapeutics, Inc. announced that, in connection with the appointment of Mark Rothera as Viracta’s new President and Chief Executive Officer, the independent members of Viracta’s Board of Directors approved the grant of a non-qualified stock option to Mr. Rothera to purchase 1,375,000 shares of common stock.

Bebird, the current leader in visual ear cleaning device sales, is pleased to announce the historic deregulation of the hearing aid industry.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.